Agios Pharmaceuticals Inc
AGIOHealthcare|Biotechnology|USA
$41.23
-1.56 (-3.65%)
Tangible Book
$40.97
About
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Stock Price
+4.3%(1Y)
Pipeline Summary
60 total trials31
Phase 1
10
Phase 2
11
Phase 3
1
Phase 4
Completed: 38Active: 11Terminated: 3NOT_YET_RECRUITING: 3Withdrawn: 1ENROLLING_BY_INVITATION: 1APPROVED_FOR_MARKETING: 1Recruiting: 2
Active Trials (13)
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
NCT04770779Transfusion-dependent Alpha-Thalassemia
Phase 3Active
Enrollment: 258 participants
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period
NCT05175105Pediatric Pyruvate Kinase Deficiency
Phase 3Active
Enrollment: 30 participants
A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia
NCT03692052Thalassemia
Phase 2Active
Enrollment: 20 participants
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
NCT05490446Myelodysplastic Syndromes
Phase 2Active
Enrollment: 87 participants
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
NCT05031780Sickle Cell Disease
Phase 2Phase 3Active
Enrollment: 286 participants
BioScore
5.2/10
Watchlist
Ownership
Recent Insider Trades
Gheuens SarahSELL
2026-07-014,007 shares @ $37.56
Burns James WilliamSELL
2026-04-023,280 shares @ $34.71
Gheuens SarahSELL
2026-04-022,940 shares @ $34.71
Jones CeciliaSELL
2026-04-023,141 shares @ $34.71
Milanova TsvetaSELL
2026-04-023,262 shares @ $34.71
Recent News
2026-07-07 16:32:40
2026-07-07 16:27:12
2026-07-07 16:26:01
2026-07-07 15:50:26
2026-07-07 14:29:06
Data last updated: Jul 13, 2026, 10:40 AM